Discovery of JNJ-88549968, a Novel, First-in-Class CALRmutxCD3 T-Cell Redirecting Antibody for the Treatment of Myeloproliferative Neoplasms

被引：8

作者：

Kuchnio, Anna ^{[1
]}

Samakai, Elsie ^{[2
]}

Hug, Eva ^{[3
]}

Balmana, Meritxell ^{[3
]}

Janssen, Lut ^{[1
]}

Amorim, Ricardo ^{[1
]}

Cornelissen, Ivo ^{[1
]}

Majoros, Andrea ^{[3
]}

Broux, Michael ^{[1
]}

Taneja, Isha ^{[2
]}

Torti, Vince ^{[4
]}

Agic, Azra ^{[3
]}

Moritsch, Stefan ^{[3
]}

Benedetti, Filippo ^{[3
]}

Rosebrock, Felix ^{[3
]}

Packman, Kathryn ^{[5
]}

Arts, Janine ^{[6
]}

Patel, Sonal ^{[7
]}

Lomas, Oliver Christopher ^{[8
]}

Deyoung, M. Phillip ^{[2
]}

Zagrijtschuk, Oleh ^{[3
]}

Elsayed, Yusri ^{[9
]}

Constantinescu, Stefan ^{[10
,11
,12
,13
]}

Kralovics, Robert ^{[14
]}

Philippar, Ulrike ^{[15
]}

机构：

[1] Janssen Res & Dev, Beerse, Belgium

[2] Janssen Res & Dev, Spring House, PA USA

[3] MyeloPro Diagnost & Res GmbH, Vienna, Austria

[4] Janssen Res & Dev, La Jolla, CA USA

[5] Janssen Res & Dev LLC, Cambridge, MA USA

[6] Janssen Sci Innovat Oncol, Beerse, Belgium

[7] Janssen Sci Innovat Oncol, London, England

[8] Janssen Res & Dev, High Wycombe, England

[9] Janssen Res & Dev LLC, Spring House, PA USA

[10] Ludwig Inst Canc Res, Brussels, Belgium

[11] UCLouvain, Duve Inst, Brussels, Belgium

[12] Wel Res Inst, Welbio Dept, Wavre, Belgium

[13] Univ Oxford, Nuffield Dept Med, Ludwig Canc Res Oxford, Oxford, England

[14] Med Univ Vienna, Vienna, Austria

[15] Janssen Res & Dev LLC, Beerse, Belgium

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-173430

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 44 条

[1] JNJ-78306358: A first-in-class bispecific T cell redirecting HLA-G antibody
Obermajer, Natasa
Zwolak, Adam
Van de Ven, Kelly
Versmissen, Shana
Brajic, Aleksandra
Petley, Ted
Weinstock, Dan
Aligo, Jason
Yi, Fang
Jarantow, Stephen
Schutsky, Keith
Tian, Ken
Lorraine, Angelilo
Arias, Diana Alvarez
Buyens, Kristel
Torti, Vince
Menard, Krista
Rogers, Katharine
Geist, Brian
Van Heerden, Marjolein
Chu, Gerald
Verbist, Bie
Ongenaert, Mate
Hasler, Julien
Packman, Kathryn
Shenton, Jacintha
Brehmer, Dirk
Lauring, Josh
Brown, Regina J.
Greger, James
Ryan, Daphne Salick
Singh, Sanjaya
Lorenzi, Matthew V.
Lenox, Laurie
Laquerre, Sylvie
CANCER RESEARCH, 2022, 82 (12)
[2] Characterization of JNJ-79635322, a Novel BCMAxGPRC5DxCD3 T-Cell Redirecting Trispecific Antibody, for the Treatment of Multiple Myeloma
Pillarisetti, Ram
Yang, Danlin
Yao, Jianhong
Smith, Melissa
Luistro, Leopoldo
Vulfson, Peter
James, Testa, Jr.
Packman, Kathryn
Brodeur, Scott
Attar, Ricardo M.
Elsayed, Yusri
Philippar, Ulrike
BLOOD, 2023, 142
[3] Discovery of JNJ-67856633: A novel, first-in-class MALT1 protease inhibitor for the treatment of B cell lymphomas
Philippar, Ulrike
Lu, Tianbao
Vloemans, Nele
Bekkers, Mariette
Van Nuffel, Luc
Gaudiano, Marcello
Wnuk-Lipinska, Katarzyna
Van der Leede, Bas-jan
Amssoms, Katie
Kimpe, Kristof
Medaer, Bart
Greway, Tony
Abraham, Yann
Cummings, Max
Trella, Emanuele
Vanhoof, Greet
Sun, Weimei
Thuring, Jan Willem
Connolly, Peter
Linders, Jan
Rui, Haopeng
Balasubramanian, Sriram
Johnson, Amy
Gerecitano, John
Goldberg, Jenna
Edwards, James P.
Elsayed, Yusri
Smit, Jennifer
Bussolari, Jaqueline
Attar, Ricardo
CANCER RESEARCH, 2020, 80 (16)
[4] A Novel CD3/BCMA Bispecific T-cell Redirecting Antibody for the Treatment of Multiple Myeloma
Xiong, Mengshang
Liu, Ruoqi
Lei, Xiaomin
Fan, Dongmei
Lin, Fangzhen
Hao, Wei
Yuan, Xiangfei
Yang, Yuanyuan
Zhang, Xiaolong
Ye, Zhou
Lu, Yang
Zhang, Yanjun
Wang, Jianxiang
Xiong, Dongsheng
JOURNAL OF IMMUNOTHERAPY, 2022, 45 (02) : 78 - 88
[5] JNJ-78306358, a first-in-class bispecific T cell engaging antibody targeting CD3 and HLA-G
Obermajer, Natasa
Zwolak, Adam
van de Ven, Kelly
Versmissen, Shana
Menard, Krista
Rogers, Katharine
Petley, Ted
Weinstock, Dan
Aligo, Jason
Patel, Jaymala
Tian, Ken
Angelillo, Lorraine
Yi, Fang
Jarantow, Stephen
Schutsky, Keith
Hamuro, Yoshitomo
Arias, Diana Alvarez
Buyens, Kristel
Yao, Tsun-Wen Sheena
Torti, Vince
Brajic, Aleksandra
Geist, Brian
van Heerden, Marjolein
Chu, Gerald
Verbist, Bie
Ongenaert, Mate
Hasler, Julien
Packman, Kathryn
Shenton, Jacintha
Lenox, Laurie
Clawson, Jacalyn
Brown, Regina J.
Lauring, Josh
Greger, James G.
Brehmer, Dirk
Singh, Sanjaya
Lorenzi, Matthew, V
Laquerre, Sylvie
ISCIENCE, 2025, 28 (03)
[6] First-in-class T cell-redirecting bispecific antibody targeting glypican-3: a highly tumor-selective antigen
Ishiguro, Takahiro
Kinoshita, Yasuko
Sano, Yuji
Azuma, Yumiko
Tsunenari, Toshiaki
Ono, Natsuki
Kayukawa, Yoko
Kamata-Sakurai, Mika
Shiraiwa, Hirotake
Kaneko, Akihisa
Frings, Werner
Komatsu, Shunichiro
Nezu, Junichi
Endo, Mika
CANCER RESEARCH, 2016, 76
[7] Characterization of JNJ-80948543, a Novel CD79bxCD20xCD3 Trispecific T-Cell Redirecting Antibody for the Treatment of B-Cell Non-Hodgkin Lymphoma
Kuchnio, Anna
Yang, Danlin
Vloemans, Nele
Lowenstein, Cassandra
Cornelissen, Ivo
Amorim, Ricardo
Han, Chao
Sukumaran, Siddharth
Janssen, Lut
Suls, Toon
Bekkers, Mariette
Lasorsa, Elena
Fontana, Lorena
Medeiros, Nicole
Wu, Bingyuan
Chen, Jun
Feldkamp, Michael
Wu, Sheng-Jiun
Habte, Habtom
Krayer, John
Holland, Cam
Deyoung, M. Phillip
Elsayed, Yusri A.
Philippar, Ulrike
BLOOD, 2022, 140 : 3105 - 3106
[8] Target Expression, Preclinical Activity and Mechanism of Action of EM801: A Novel First-in-Class Bcma T-Cell Bispecific Antibody for the Treatment of Multiple Myeloma
Seckinger, Anja
Delgado, Jose Antonio
Moreno, Laura
Neuber, Brigitte
Grab, Anna
Lipp, Susanne
Merino, Juana
Vu, Minh Diem
Strein, Klaus
Prosper, Felipe
Hundemer, Michael
Miguel, Jesus San
Hose, Dirk
Paiva, Bruno
BLOOD, 2015, 126 (23)
[9] Targeting CD39 with a first-in-class inhibitory antibody prevents ATP processing and increases T-cell activation
Lerner, Alana G.
Kovalenko, Maria
Welch, Megan
Dela Cruz, Tracy
Jones, Jeff
Wong, Clifford
Spatola, Bradley
Eberhardt, Meghan
Wong, Andrew
Fung, Wanchi
Lagpacan, Leanna
Losenkova, Karolina
Yegutkin, Gennady
Soros, Vanessa
Corbin, John
Beers, Courtney
Moesta, Achim K.
CANCER RESEARCH, 2019, 79 (13)
[10] Combination therapy of JNJ-67856633, a novel, first-in-class MALT1 protease inhibitor, and JNJ-64264681, a novel BTK inhibitor, for the treatment of B-cell lymphomas.
Philippar, Ulrike
Fontan, Lorena
Cornelissen, Ivo
Rui, Haopeng
Balasubramanian, Sriram
Gaudiano, Marcello
Bekkers, Mariette
Van Nuffel, Luc
Lu, Tianbao
Lu, Tianbao
Wiener, John
Tichenor, Mark
Greway, Tony
Packman, Kathryn
Verbist, Bie
Elsayed, Yusri
Attar, Ricardo
Bussolari, Jacqueline
Gerecitano, John
CANCER RESEARCH, 2021, 81 (13)

← 1 2 3 4 5 →